Rehospitalization is common among patients with peripheral arterial disease (PAD) after peripheral arterial revascularization, according to a study published online December 5 in the Annals of ...

More than one in six patients who undergo revascularization for PAD return to the hospital within 30 days, according to a nationwide cohort study. Researchers found few differences in readmission ...

Please provide your email address to receive an email when new articles are posted on . In a retrospective analysis of patients with peripheral artery disease from a single-payer system, endovascular ...

The study, Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (VOYAGER-PAD), was designed to fill a knowledge gap: it asked whether a well ...

Following an emergency lower limb revascularization, people with PAD who are in their 50s have a higher risk than those in their 80s of needing major amputation, according to a large analysis of ...

Things seem to be looking up for the field of endovascular revascularization for symptomatic peripheral artery disease (PAD), researchers suggested. Paclitaxel-coated devices were safe for patients ...

BOSTON - Peripheral arterial disease (PAD), a vascular condition that prevents blood flow to the extremities, currently affects 8.5 million people in the United States. A study of nearly 62,000 ...

Long Beach, Calif. – May 3, 2024 – New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including ...

Xarelto, a Factor Xa inhibitor, is currently indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Janssen announced positive results from the ...

Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

RARITAN, N.J., Aug. 24, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ...

Please provide your email address to receive an email when new articles are posted on . More than 1 in 6 patients undergoing peripheral revascularization for peripheral artery disease were readmitted ...